Karen J. Ferrante, MD

Dr. Ferrante is a hematologist-oncologist with 25 years of experience in oncology drug development and the pharmaceutical industry. She was the former Chief Medical Officer and Head of Research and Development of Tokai Pharmaceuticals, Inc. and Head of the Oncology Therapeutic Area at Takeda and CMO at Millennium Pharmaceuticals, after holding a variety of roles in oncology clinical development at Pfizer, Inc. and BMS. Dr. Ferrante is currently a member of the board of directors of MacroGenics, Inc., Cogent Biosciences and Chi-Med. She was a director of Progenics, Inc., (acquired by Lantheus Holdings) and Baxalta, Inc., (acquired by Shire). She is a member of the SAB for Kazia Therapeutics and was previously a clinical advisor to Taris Biomedical (acquired by Johnson and Johnson) and Checkmate Pharmaceuticals.

Dr. Ferrante holds a Bachelor of Science degree from Providence College and a Doctor of Medicine from Georgetown University.